Abstract
The emergence of personalised medicine (PM) indicates a potential transformative point to a greater efficiency in Southeast Asia (SEA)’s healthcare. This research aims to provide PM-related evidence to policymakers, to facilitate an informed adoption decision and improve policies underpinning PM adoption in SEA. Cost-effectiveness evidence was generated for two PM interventions, and the current PM adoption landscape in SEA was described. Adopting PM remains in its infancy in SEA. Local health technology assessment should consider cost-effectiveness evidence and broader societal impacts of PM for an informed decision-making. Substantial future work is needed to support an efficient, equitable PM adoption.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
